Abnova (Taiwan) Corporation (4133.TW)
Taiwan · TWD · Healthcare · Biotechnology
NT$20.70 (+0.49%) as of
Key statistics
- Market cap
- 1.25B
- P/E (TTM)
- 27.97
- Forward P/E
- 16.97
- EPS (TTM)
- 0.74
- Dividend yield
- 0.54%
- 52-week range
- 20.00 – 29.15
- Beta
- 0.27
- Revenue (TTM)
- 345.45M
- Profit margin
- 12.99%
- Volume
- 65.10k
About Abnova (Taiwan) Corporation
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, Nano, DNAxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company provides integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production and scale up; assay development services; circulating tumor cell and DNA; germline genetic DNA; and FFPE tumor tissue DNA services. It serves academic, research institutions, and pharmaceutical factories. Abnova (Taiwan) Corporation was founded in 2002 and is headquartered in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.